8-K: Biomea Fusion Unveils Promising Diabetes, Obesity Drug Data

Biomea Fusion presented positive 52-week data for its diabetes drug Icovamenib and preclinical results for its obesity candidate BMF-650 at the J.P. Morgan Healthcare Conference.

Summary

• Biomea Fusion presented updates on its lead drug candidates, Icovamenib for Type 2 Diabetes (T2D) and BMF-650 for obesity, at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Icovamenib, an oral menin inhibitor, demonstrated durable and clinically significant improvements in HbA1c in severe insulin-deficient T2D patients, with a 1.2% mean reduction (p=0.01) maintained through Week 52 after only 12 weeks of dosing.
• In T2D patients not controlled on GLP-1 based therapies, Icovamenib showed a 1.3% mean HbA1c reduction (p=0.05) maintained through Week 52 after 12 weeks of dosing.
• Icovamenib increased insulin secretion, as measured by C-peptide Index, by 29% in severe insulin-deficient patients compared to 2% for placebo, nine months after the last dose.
• The company plans to initiate two Phase II trials for Icovamenib (COVALENT-211 for insulin-deficient T2D and COVALENT-212 for T2D patients not controlled on GLP-1 therapies) with first patient enrollment planned for Q1 2026 and 26-week readouts expected in Q4 2026.
• BMF-650, an oral GLP-1 receptor agonist, showed strong dose-dependent body weight reduction in obese cynomolgus monkeys, with reductions of 12.3% (10mg/kg) and 15.2% (30mg/kg) over 29 days, compared to 3.4% for vehicle.
• BMF-650 demonstrated a favorable liver safety profile in preclinical studies and the ongoing Phase I trial, contrasting with other GLP-1 RAs that faced LFT elevation issues.
• Phase I results for BMF-650 (GLP-131 study) on 28-day weight loss are expected in Q2 2026.
• A US patent application covering BMF-650 received allowance in mid-December 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for Icovamenib, indicating durable efficacy and a favorable safety profile, with a novel mechanism of action. BMF-650 also shows promising preclinical results and a good safety profile, addressing a high-demand market. The planned progression to Phase II trials for Icovamenib and upcoming Phase I data for BMF-650 suggest significant future catalysts. The patent allowance for BMF-650 is also a positive. The main caveats are the cross-study comparisons and the early stage of BMF-650's clinical development.

Positives

• Icovamenib demonstrated durable and clinically significant HbA1c reductions of 1.2% (p=0.01) in severe insulin-deficient T2D and 1.3% (p=0.05) in GLP-1 failure patients, maintained 9 months post-treatment.
• Icovamenib increased insulin secretion by 29% in severe insulin-deficient patients, indicating beta-cell regeneration.
• Icovamenib exhibited a favorable safety profile through 52 weeks, with no treatment-related serious adverse events or discontinuations.
• BMF-650 showed strong preclinical weight loss, reducing body weight by up to 15.2% in obese cynomolgus monkeys.
• BMF-650 has a favorable liver safety profile to date, distinguishing it from other oral GLP-1 RAs that faced LFT elevation issues.
• The company received US patent allowance for BMF-650, strengthening its intellectual property.
• Icovamenib's mechanism of action targets the root cause of T2D (beta-cell failure) and offers a non-chronic, short-term treatment approach.
• Cross-study comparisons suggest Icovamenib's HbA1c reductions are comparable to chronic injectable and oral standards of care.

Negatives

• The HbA1c reduction data for GLP-1 based therapy failures was from a post-hoc analysis (n=11), which requires further validation in dedicated trials.
• The comparisons to other approved T2D agents are cross-study and not from head-to-head trials, which inherently limits direct comparability.
• BMF-650's clinical data is still in Phase I, with 28-day weight loss results pending.

Risks

• Preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with ongoing or future clinical trials.
• Delays may be encountered in preclinical or clinical development, patient enrollment, and in the initiation, conduct, and completion of ongoing and planned clinical trials and other research and development activities.
• Projections, assumptions, and estimates of future performance and market performance are subject to a high degree of uncertainty and risk.
• Actual results could differ materially and adversely from forward-looking statements due to various risks and uncertainties.

Future Outlook

Biomea Fusion plans to advance its clinical pipeline with the first patient enrollment for two Phase II trials of Icovamenib (COVALENT-211 and COVALENT-212) in Q1 2026, with 26-week data readouts anticipated in Q4 2026. For BMF-650, 28-day weight loss results from the Phase I GLP-131 study are expected in Q2 2026. The company aims to restore endogenous insulin production with Icovamenib and provide effective, well-tolerated oral weight loss with BMF-650.

Management Comments

• Icovamenib's recent data has shown an impressive restoration of beta cell function as demonstrated by significant elevations in C-peptide even after the treatment period ended.
• The icovamenib data looks exciting. The data presented today help to confirm icovamenib's mechanism of action. We have not previously seen data like this with any antihyperglycemic agent.
• Great foray into precision medicine. We need to be addressing patients in a much more individualized manner. By addressing insulin-deficient diabetes patients with icovamenib, we have seen post treatment that the beta cell pool is being restored and producing a higher level of insulin, as measured by C-peptide.
• This indicates a fundamental and potentially lasting impact on the disease and validates the mechanism of action of menin inhibition.
• We do not have an agent today that addresses one of the root cause of diabetes beta cell dysfunction icovamenib would be the first.
• Patients are achieving lasting benefits without continuous chronic dosing, suggesting that icovamenib may be disease modifying. I am very impressed.
• The icovamenib data are quite interesting because of the continued effects despite having stopped it. Usually, one would expect to see the HbA1c levels climb towards baseline when the medication is stopped, but with icovamenib, the HbA1c levels decreased, which is quite intriguing and unprecedented.
• Icovamenib is a very interesting molecule that acts quite differently than anything I have seen before. We are observing glucose controlled and beta cell-specific proliferation and an increase in stimulated C-peptide secretion leading to patient benefits that continued after the icovamenib dosage ended.
• I am very excited to further explore the many opportunities that the covalent inhibition of menin will provide to patients.

Industry Context

The announcement positions Biomea Fusion as a potential innovator in the metabolic disease space, particularly with Icovamenib's novel approach to T2D by targeting beta-cell regeneration, which could differentiate it from existing symptom-focused therapies. BMF-650 aims to address the significant unmet need for effective and well-tolerated oral GLP-1 receptor agonists for obesity, a market currently dominated by injectables and facing tolerability challenges with some oral candidates.

Comparison to Industry Standards

• Icovamenib's 12-week oral treatment resulted in HbA1c reductions of -1.5% to -1.8% at Week 52, which compares favorably to chronic injectable GLP-1 agonists like Ozempic (-1.2% to -1.4% at Week 30) and Mounjaro (-1.7% to -1.8% at Week 40).
• Icovamenib's performance also appears superior to chronic oral therapies such as Jardiance (SGLT2 inhibitor, -0.7% to -0.9% at Week 24) and Januvia (DPP4 inhibitor, -0.8% at Week 24).
• BMF-650, an oral GLP-1 RA, is being developed within the Chugai chemotype, which has shown no liver function test (LFT) signals (e.g., orforglipron with 3000+ patients dosed). This contrasts with the Pfizer chemotype (danuglipron, lotiglipron) and TERN-601, which were discontinued due to LFT elevations.
• Preclinical weight loss for BMF-650 in obese cynomolgus monkeys (up to 15.2% reduction) appeared favorable in cross-study comparison with CT-996 (Roche/Carmot).

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to promising clinical data, advancement of pipeline, and strengthened intellectual property, suggesting future growth.
• Patients (Diabetes): Icovamenib offers a potential disease-modifying, non-chronic oral treatment option that could restore natural insulin production, improving long-term outcomes and quality of life.
• Patients (Obesity): BMF-650 could provide a more tolerable and effective oral GLP-1 RA option, addressing a significant unmet need in weight management.
• Healthcare Providers: New therapeutic options could enhance treatment strategies for T2D and obesity, particularly for patients not responding to current standards of care.

Next Steps

• First patient enrollment for COVALENT-211 (Phase IIb in insulin-deficient T2D) planned in Q1 2026.
• First patient enrollment for COVALENT-212 (Phase II in T2D patients not controlled on GLP-1 based therapies) planned in Q1 2026.
• Expected 26-week readout for COVALENT-211 and COVALENT-212 in Q4 2026.
• Expected 28-day weight loss study results for GLP-131 (Phase I for BMF-650) in Q2 2026.
• Continue dosing in the single ascending dose (SAD) part of the GLP-131 Phase I study.

Key Dates

Recommendation

The filing presents highly compelling and potentially transformative data for Biomea Fusion's lead diabetes candidate, Icovamenib, demonstrating durable efficacy and a favorable safety profile with a novel, disease-modifying mechanism. The ability to achieve sustained HbA1c reductions and increased insulin secretion after only a 12-week oral treatment period, maintained for 9 months post-treatment, is unprecedented and positions Icovamenib as a potential game-changer in T2D, especially for insulin-deficient patients and those failing GLP-1 therapies. Furthermore, the preclinical data for BMF-650 in obesity, coupled with its favorable liver safety profile and recent patent allowance, indicates strong potential in a rapidly growing market. The upcoming Phase II trial initiations for Icovamenib and Phase I data for BMF-650 represent significant near-term catalysts. Given the strong clinical evidence, novel mechanisms, and large addressable markets, the company is undervalued relative to its potential, warranting a strong buy recommendation for long-term investors.

Keywords

Biomea Fusion, Icovamenib, BMF-650, Type 2 Diabetes, Obesity, Menin Inhibitor, GLP-1 Receptor Agonist, Beta-Cell Regeneration, HbA1c, Weight Loss, Clinical Trials, Phase II, Phase I, Metabolic Disease, Drug Development, Biotechnology, Pharmaceuticals